12:00 AM
 | 
Nov 18, 2013
 |  BC Week In Review  |  Company News  |  Other News

Pfizer, Sanofi pulmonary, autoimmune news

The U.S. Court of Appeals for the Federal Circuit ruled that a patent covering cDNA should be awarded to the party "who first had in hand the actual isolated DNA," regardless of whether the party has correctly sequenced the segment. In 1995, Sanofi submitted a patent application for an isolated DNA polynucleotide encoding the IL-13 binding chain and Pfizer submitted an application for...

Read the full 291 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >